Date: 2015-06-08
Type of information: Nomination
Compound:
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 8, 2015, Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, has strengthened its executive leadership with the appointment of two new senior members of the commercial and executive team. Mark Baldry, a biopharmaceutical brand strategist with senior-level experience at Biogen Inc. and Shire plc, has joined the Company as Vice President of Global Marketing. Mr. Baldry has more than 25 years experience in the life science industry and joins Amicus from Biogen Inc., where he most recently served as Vice President, Public Affairs and previously as Vice President, New Product Commercialization. Prior to Biogen, Mr. Baldry held roles of increasing responsibility at Shire plc, including Head of Marketing, Market Access, and Public Affairs, Europe, Middle East and Africa (EMEA) for the Human Genetic Therapies division. Mr. Baldry will be responsible for building and managing the global marketing team and brand strategy for Galafold™ (migalastat) for Fabry disease, as well as future products commercialized by Amicus. Willem van Weperen, most recently the former Chief Commercial Officer of Prosensa Holding N.V., has been appointed Regional Vice President and Country Manager, International. Mr. van Weperen has more than 20 years of experience and most recently served as Chief Commercial Officer of Prosensa Holding N.V. (acquired by BioMarin). Previously, he was Head of Global Marketing in the rare genetic disease business unit at Genzyme and General Manager of Genzyme Netherlands. Mr. van Weperen will be responsible for managing the commercial launch of Galafold for Fabry disease in the Netherlands, Belgium and several Central & Eastern European countries, as well as Middle East, Africa, Asia Pacific and Latin America. Additionally, Hung Do, Ph.D. has been promoted to Chief Science Officer. Dr. Do will continue to lead the research and preclinical development efforts for Amicus\' pipeline of next-generation enzyme-replacement therapies (ERTs) for lysosomal storage disorders, led by the Pompe program, and will take on additional responsibilities in overseeing the entire Science department. Dr. Do has nearly 17 years of experience in the field of lysosomal storage disorders and ERTs while working at Novazyme, Genzyme, Amicus, and Callidus. He re-joined Amicus in November 2013 as Senior Vice President, Discovery Biology following Amicus\' acquisition of Callidus BioPharma, a biologics company that he co-founded.
Financial terms:
Latest news:
